Health Care & Life Sciences » Biotechnology | Endonovo Therapeutics Inc.

Endonovo Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
22.90
24.20
4.30
-
-
83.30
Cost of Goods Sold (COGS) incl. D&A
14.00
31.20
16.90
15.80
14.80
663.10
Gross Income
8.90
7.00
12.70
15.80
14.80
579.90
SG&A Expense
2,437.60
2,184.20
2,552.00
5,395.10
4,589.10
3,579.40
EBIT
2,428.70
2,191.20
2,564.70
5,410.90
4,603.90
4,159.30
Unusual Expense
197.80
-
2,659.20
2,490.00
417.00
2,920.50
Non Operating Income/Expense
1.80
1,410.60
-
-
-
-
Interest Expense
267.60
178.80
1,541.90
2,394.80
5,789.30
5,197.10
Pretax Income
2,892.30
959.50
6,765.70
5,315.70
10,810.20
6,435.80
Income Tax
0.50
-
-
-
-
-
Consolidated Net Income
2,892.80
959.50
6,765.70
5,315.70
10,810.20
6,435.80
Net Income
2,892.80
959.50
6,765.70
5,315.70
10,810.20
6,435.80
Net Income After Extraordinaries
2,892.80
959.50
6,765.70
5,315.70
10,810.20
6,435.80
Net Income Available to Common
2,892.80
959.50
6,765.70
5,315.70
10,810.20
6,435.80
EPS (Basic)
4.15
0.03
0.07
0.05
0.04
0.02
Basic Shares Outstanding
697.30
30,288.00
96,844.50
117,405.90
242,090.40
362,466
EPS (Diluted)
4.15
0.03
0.07
0.05
0.04
0.02
Diluted Shares Outstanding
697.30
30,288.00
96,844.50
117,405.90
242,090.40
362,466
EBITDA
2,416.80
2,175.50
2,549.90
5,395.10
4,589.10
3,509

About Endonovo Therapeutics

View Profile
Address
6320 Canoga Avenue
Woodland Hills California 91367
United States
Employees -
Website http://www.endonovo.com
Updated 07/08/2019
Endonovo Therapeutics, Inc. is a biotechnology company, which engages in developing off bioelectronic approach to regenerative medicine. It operates through the Intellectual Property Management and Commercialization segment. The company was founded on May 26, 2011 and is headquartered in Woodland Hills, CA.